Alzheimer Testing at Silver Years
THOMAS a1, GENE
COHEN a2, ROBERT M.
COOK-DEEGAN a3, JOAN
O'SULLIVAN a4, STEPHEN G.
POST a5, ALLEN D.
ROSES a6, KENNETH F.
SCHAFFNER a7 and RONALD M.
a1 Harvard University
a2 Center on Aging, Health, and the Humanities at
the George Washington University
a3 National Cancer Policy Board, National Academy of
Sciences and Institute of Medicine
a4 University of Maryland Law School
a5 Ethical, Legal, and Social Implications Program of the
National Human Genome Research Institute and the Center for
Biomedical Ethics, School of Medicine, Case Western Reserve
a6 Glaxo Wellcome
a7 George Washington University,
a8 Ethics Institute at Dartmouth College,
Hanover, New Hampshire
Early last year, the GenEthics Consortium (GEC)
of the Washington Metropolitan Area convened at George
Washington University to consider a complex case about
genetic testing for Alzheimer disease (AD). The GEC consists
of scientists, bioethicists, lawyers, genetic counselors,
and consumers from a variety of institutions and affiliations.
Four of the 8 co-authors of this paper delivered presentations
on the case. Supplemented by additional ethical and legal
observations, these presentations form the basis for the